Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury

Curr Mol Med. 2008 Sep;8(6):562-79. doi: 10.2174/156652408785748022.

Abstract

Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands constitute important insulin sensitizers that have already been used for the treatment of human metabolic disorders, exerting also pleiotropic effects on inflammatory related diseases and cancer. Ischemia-reperfusion injury that is mainly associated with organ transplantation constitutes a serious complication with a great relevance in clinical practice. Accumulating experimental data have recently revealed that natural and synthetic PPAR-gamma ligands exert beneficial effects against ischemia-reperfusion injury. The present review summarizes the available information on the role of PPAR-gamma ligands in ischemia-reperfusion injury amongst the different organ systems. Taking into consideration the data so far, PPAR-gamma ligands seem to represent potential therapeutic agents in the aim to reduce or even prevent injury associated with ischemia-reperfusion.

Publication types

  • Review

MeSH terms

  • Brain / metabolism
  • Brain / pathology
  • Cardiovascular System / metabolism
  • Cardiovascular System / pathology
  • Gastrointestinal Tract / metabolism
  • Gastrointestinal Tract / pathology
  • Humans
  • Inflammation / metabolism
  • Kidney / metabolism
  • Kidney / pathology
  • Ligands
  • Lung / metabolism
  • Lung / pathology
  • NF-kappa B / metabolism
  • Neutrophils / metabolism
  • Nitric Oxide / metabolism
  • PPAR gamma / metabolism*
  • Reactive Oxygen Species / metabolism
  • Reperfusion Injury / pathology
  • Reperfusion Injury / physiopathology
  • Reperfusion Injury / therapy*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Ligands
  • NF-kappa B
  • PPAR gamma
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide